The FDA has issued an Early Alert for GE HealthCare’s Giraffe and Panda infant resuscitation systems, warning that a component inside the air-oxygen blender can loosen and cause the device to deliver an oxygen concentration that does not match what the clinician set.
The alert covers Giraffe and Panda Warmers fitted with the Integrated Resuscitation System (iRes) and the Giraffe Stand-alone Infant Resuscitation System, specifically units containing the M1091607-R blender. Per the FDA notice, the air-oxygen blender knob shaft on certain systems can loosen, affecting the delivered oxygen concentration so that it does not match the user’s set concentration — potentially resulting in hypoxia or hyperoxia in the patient.
That failure mode is unforgiving in the population it serves. Titrated oxygen is central to neonatal resuscitation: too little risks hypoxic injury, while excess oxygen exposure in newborns — particularly preterm infants — is linked to oxidative harm. A blender that silently drifts off its set point undermines the one control clinicians rely on most in the first minutes of life.
What the alert says, and what it doesn’t
GE HealthCare sent affected customers a letter dated May 8, 2026. The FDA flagged the issue publicly on June 8, 2026 — about a month later — through an Early Alert, which the agency describes as a notice about a potentially high-risk device issue.
As of May 20, 2026, GE HealthCare has not reported any serious injuries or deaths associated with this issue.
The FDA’s recommended actions: inspect Giraffe and Panda iRes and stand-alone resuscitation systems to determine whether a unit contains an affected blender, and if so, remove it from patient use and contact a GE HealthCare service representative. U.S. customers can reach GE HealthCare Service at 1-800-437-1171.
For units that must remain in service while awaiting correction, the FDA describes an interim mitigation: perform the system’s pre-use checkout and Multipoint Oxygen Concentration Check as outlined in the user manual, and if those pass, GE HealthCare recommends verifying oxygen concentration with an independent oxygen analyzer on a frequent basis until the unit is corrected. This step does not substitute for removing an affected unit, but it guards against undetected drift in the interim.
The number of affected units and the distribution timeline were not disclosed in the alert.
For now, the practical signal for neonatal and NICU teams is concrete: confirm whether your resuscitation systems carry the M1091607-R blender, run the pre-use checkout and Multipoint Oxygen Concentration Check, verify delivered oxygen with an independent analyzer frequently on any unit still in use, and remove and report affected units per the FDA’s guidance.